Experimental Human Pneumococcal Challenge With SPN3
Key facts
- Who runs it
- Liverpool School of Tropical Medicine
- Where
- United Kingdom1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 91 people enrolled
- Started
- 1 Aug 2022
- Ended
- 21 Nov 2023
- Type of study
- Interventional, 6 groups
- Treatments tested
- Serotype 3 Experimental Human Pneumococcal Challenge - Liverpool Isolate (LIV014-S3)
- Serotype 3 Experimental Human Pneumococcal Challenge - Malawi Isolate (MLW-10V)
- Record updated
- 29 June 2026
Who can take part
- Age
- 18 years to 50 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Fluent spoken English - to ensure a comprehensive understanding of the research project and their proposed involvement, enabling valid consent to be given
- Access to their own mobile telephone - to ensure safety and timely communication
- Capacity to give informed consent
Who cannot take part
- o Currently involved in another study unless observational or non-interventional, excluding the EHPC bronchoscopy study (at the discretion of the study team). This is to ensure no harm comes to the participants through over-sampling; Participant in any previous EHPC trial in past year; Participant in previous EHPC trial inoculated with SPN3 in the last 3 years; Participant in EHPC Pneumo 2 trial; Vaccination: Previous pneumococcal vaccination PPV23 or PCV13 (routine in babies born in the UK since 2005) or PCV10. This can be self-reported or confirmed from GP questionnaire (GPQ) if deemed necessary at clinician discretion; Allergy: to penicillin/amoxicillin; Health history (self-reported or confirmed by GPQ or medical summary if felt to be necessary at clinician discretion):; Chronic ill health including immunosuppressive history, diabetes, asthma (on regular medication), recurrent otitis media or other respiratory disease; Medication that may affect the immune system e.g., steroids, inflammation altering or disease-modifying anti-rheumatoid drugs; Long term use of antibiotics for chronic infection; Major pneumococcal illness requiring hospitalisation in the last 10 years; Other conditions considered by the clinical team as a concern for participant safety or integrity of the study; Significant mental health problems (uncontrolled condition or requiring previous admission to a psychiatric unit) that would impair ability to participate; Direct caring role or close contact with individuals at higher risk of infection during the inoculation period if personal protective equipment (PPE) not worn:; Children under 5 years age; Adults with chronic ill health or immunosuppression; Hospital patients; Smoker:; Current or ex-smoker (daily cigarettes, daily e-cigarettes/vaping and daily smoking of recreational drugs) in the last 6 months. Participants who smoke <5 cigarettes per week may be included; Previous significant smoking history (>20 cigarettes per day for 20 years or equivalent [>20 pack years]); Biologically female participants of child-bearing potential (WOCBP) who are:; Currently pregnant/lactating; Intending on becoming pregnant during the study; Not deemed to have effective birth control; History of or current drug or alcohol abuse:; Men should not drink >3 units/day regularly; Women should not drink >2 units/day regularly; Overseas travel planned in follow up period of study visits; Natural SPN 3 colonisation in baseline nasal wash - if a participant is colonised with non-SPN3 pneumococcus, they can be included as part of exploratory analyses, but would not be included in the primary analysis; STOP criteria - participants who meet STOP criteria at time of screening (Table 3) 6.3 Temporary Exclusion Criteria; Ongoing COVID-19 symptoms (fever, cough, shortness of breath, anosmia or ageusia) or confirmed current COVID-19 infection. Participants with resolved COVID-19 after their UKHSA determined isolation period has ended can be included; Current/acute illness within 14 days prior to inoculation if COVID-19 negative; Positive COVID-19 swab whether symptomatic or asymptomatic within 10 days of inoculation; Currently isolating following exposure to COVID-19 as per UKHSA guidance; Antibiotic use within 28 days of inoculation; Participants who have been temporarily excluded at screening may be re-screened at a later date to assess their eligibility at this time for inclusion into the study. At this point, the participant would be re-consented if their initial written consent was given >4 months prior to this date; Vaccination 21 days prior to inoculation
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The 'Experimental Human Pneumococcal challenge' (EHPC) model is a way of putting drops of bacteria into the nose. Investigators have studied this model of putting bacteria in the nose safely in over 1500 volunteers over the past decade with no serious side effects and now want to test the model using a different strain of the bacteria that is commonly found in the community, SPN3.
Read full original descriptionShow less
The aim of this study is to determine how much pneumococcus is needed to achieve nasal colonisation and how long the bacteria live in the nose for before natural immune responses eradicate them. By doing this, Investigators will then be able to test how well future vaccines prevent colonisation with pneumococcus. Investigators want to learn more about how the immune system responds to nasal colonisation with pneumococcus, again to help with development of new vaccines.
The 6 groups in the trial
- MLW-10V, 10000 CFU/mlTreatment being tested
Malawi isolate, low dose
Treatment: Serotype 3 Experimental Human Pneumococcal Challenge - Malawi Isolate (MLW-10V)
- MLW-10V, 20000 CFU/mlTreatment being tested
Malawi isolate, intermediate dose
Treatment: Serotype 3 Experimental Human Pneumococcal Challenge - Malawi Isolate (MLW-10V)
- MLW-10V, 80000 CFU/mlTreatment being tested
Malawi isolate, higher dose
Treatment: Serotype 3 Experimental Human Pneumococcal Challenge - Malawi Isolate (MLW-10V)
- LIV014-S3, 10000 CFU/mlTreatment being tested
Liverpool isolate, low dose
Treatment: Serotype 3 Experimental Human Pneumococcal Challenge - Liverpool Isolate (LIV014-S3)
- LIV014-S3, 20000 CFU/mlTreatment being tested
Liverpool isolate, intermediate dose
Treatment: Serotype 3 Experimental Human Pneumococcal Challenge - Liverpool Isolate (LIV014-S3)
- LIV014-S3, 80000 CFU/mlTreatment being tested
Liverpool isolate, higher dose (includes dose-ranging and reproducibility study participants, since the reproducibility study only included this isolate and dose)
Treatment: Serotype 3 Experimental Human Pneumococcal Challenge - Liverpool Isolate (LIV014-S3)
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Serotype 3 Experimental Human Pneumococcal Challenge; Dose Ranging and Reproducibility in a Healthy Volunteer Population
- Record updated
- 29 June 2026